In March 2025, the company introduced new ideas for any direct-to-purchaser offering of its Wegovy weight loss drug. The company recognized a new pharmacy, called NovoCare, which would charge buyers $499 per 30 days for access to the drug, less than 50 % the expense of the drug as a result of other pharmaceutical distribution networks.[fifty three]